William Christopher Lamanna | Laboratory Head of Protein Characterization
Sandoz Inc

William Christopher Lamanna, Laboratory Head of Protein Characterization, Sandoz Inc

Professional experience 

08/2016-present    Global Scientific Affairs Manager (Sandoz Biopharmaceuticals)

•    Scientific input for development and approval strategies. 
•    Interactions with stakeholders worldwide (health authorities, healthcare professionals, trade associations and patient groups) to improve access and understanding for biosimilar medicines. 

10/2012-07/2016    Lab Head and Project analyst (Sandoz Biopharmaceuticals)

•      Head of analytical lab for the physicochemical characterization of biopharmaceuticals. 
•    Coordination of analytics and projects goals across international development and production sites. 

09/2008-06/2012    Postdoctoral Researcher (University of California, San Diego, USA) 
    
•    Development of diagnostics and treatment strategies for rare metabolic diseases (lysosomal storage disorders).  

09/2004-07/2008    Doctoral Research (Georg-August University Göttingen, Deutschland)

•    Cloning, expression, purification and characterization of disease relevant enzymes (sulfatases).    

    Education

09/2004-07/2008    Doctorate (Dr. rer. nat.), Georg-August University Göttingen (Germany)


07/2003-07/2004    Fulbright scholar, Georg-August University Göttingen (Germany)


09/1998-05/2003    Bachelor of Science, University of Wisconsin Eau Claire (USA)

    


    Awards

07/2010-06/2012    National Research Service Award (NRSA)
    Institute: National Institutes of Health 
    
          
09/2003-07/2004    Fulbright Scholarship    
    Institute: U.S. Department of State    

Appearances:



Biosimilars Day 2 - Wednesday 1st November 2017 @ 11:25

Originator variability and biosimilarity: Lessons learned from the approval of Erelzi in the US

  • The importance of understanding structure – function relationships in biosimilars
  • What is known about the analytical variability of biopharmaceuticals
  • Appropriate tools for assessing biosimilarity (equivalence testing vs min/max and the Erelzi experience)

back to speakers